Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:15015614rdf:typepubmed:Citationlld:pubmed
pubmed-article:15015614lifeskim:mentionsumls-concept:C0006142lld:lifeskim
pubmed-article:15015614lifeskim:mentionsumls-concept:C0346979lld:lifeskim
pubmed-article:15015614lifeskim:mentionsumls-concept:C0231220lld:lifeskim
pubmed-article:15015614lifeskim:mentionsumls-concept:C0677874lld:lifeskim
pubmed-article:15015614lifeskim:mentionsumls-concept:C0205082lld:lifeskim
pubmed-article:15015614lifeskim:mentionsumls-concept:C0728747lld:lifeskim
pubmed-article:15015614lifeskim:mentionsumls-concept:C0086960lld:lifeskim
pubmed-article:15015614lifeskim:mentionsumls-concept:C0205210lld:lifeskim
pubmed-article:15015614lifeskim:mentionsumls-concept:C1533148lld:lifeskim
pubmed-article:15015614pubmed:issue1lld:pubmed
pubmed-article:15015614pubmed:dateCreated2004-3-12lld:pubmed
pubmed-article:15015614pubmed:abstractTextOverexpression of HER-2/neu in breast cancer has been associated with more aggressive disease and poor overall survival. Trastuzumab, a recombinant humanized monoclonal antibody with high affinity for the HER-2 protein, inhibits the growth of breast cancer cells overexpressing HER-2. Trastuzumab showed, as second-line treatment, 15% of objective response in metastatic breast cancer. Bone marrow metastases are detectable in 23% of the patients with advanced breast cancer at first relapse and this rate increases in patients with metastatic disease. We report a case of a complete response of bone marrow metastases from breast cancer using a 3-weekly trastuzumab schedule, in a heavily pretreated patient with severe symptomatic pancytopenia.lld:pubmed
pubmed-article:15015614pubmed:languageenglld:pubmed
pubmed-article:15015614pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15015614pubmed:citationSubsetIMlld:pubmed
pubmed-article:15015614pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15015614pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15015614pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15015614pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15015614pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15015614pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15015614pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15015614pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15015614pubmed:statusMEDLINElld:pubmed
pubmed-article:15015614pubmed:issn0250-7005lld:pubmed
pubmed-article:15015614pubmed:authorpubmed-author:MishikA NANlld:pubmed
pubmed-article:15015614pubmed:authorpubmed-author:RossiAntonioAlld:pubmed
pubmed-article:15015614pubmed:authorpubmed-author:GridelliCesar...lld:pubmed
pubmed-article:15015614pubmed:authorpubmed-author:PanicoLuigiLlld:pubmed
pubmed-article:15015614pubmed:authorpubmed-author:CantoreNicola...lld:pubmed
pubmed-article:15015614pubmed:authorpubmed-author:De...lld:pubmed
pubmed-article:15015614pubmed:authorpubmed-author:FerboUmbertoUlld:pubmed
pubmed-article:15015614pubmed:issnTypePrintlld:pubmed
pubmed-article:15015614pubmed:volume24lld:pubmed
pubmed-article:15015614pubmed:ownerNLMlld:pubmed
pubmed-article:15015614pubmed:authorsCompleteYlld:pubmed
pubmed-article:15015614pubmed:pagination317-9lld:pubmed
pubmed-article:15015614pubmed:dateRevised2011-11-17lld:pubmed
pubmed-article:15015614pubmed:meshHeadingpubmed-meshheading:15015614...lld:pubmed
pubmed-article:15015614pubmed:meshHeadingpubmed-meshheading:15015614...lld:pubmed
pubmed-article:15015614pubmed:meshHeadingpubmed-meshheading:15015614...lld:pubmed
pubmed-article:15015614pubmed:meshHeadingpubmed-meshheading:15015614...lld:pubmed
pubmed-article:15015614pubmed:meshHeadingpubmed-meshheading:15015614...lld:pubmed
pubmed-article:15015614pubmed:meshHeadingpubmed-meshheading:15015614...lld:pubmed
pubmed-article:15015614pubmed:meshHeadingpubmed-meshheading:15015614...lld:pubmed
pubmed-article:15015614pubmed:meshHeadingpubmed-meshheading:15015614...lld:pubmed
pubmed-article:15015614pubmed:meshHeadingpubmed-meshheading:15015614...lld:pubmed
pubmed-article:15015614pubmed:meshHeadingpubmed-meshheading:15015614...lld:pubmed
pubmed-article:15015614pubmed:meshHeadingpubmed-meshheading:15015614...lld:pubmed
pubmed-article:15015614pubmed:meshHeadingpubmed-meshheading:15015614...lld:pubmed
pubmed-article:15015614pubmed:articleTitleComplete response of severe symptomatic bone marrow metastases from heavily pretreated breast cancer with a 3-weekly trastuzumab schedule. A clinical case.lld:pubmed
pubmed-article:15015614pubmed:affiliationU.O. Oncologia Medica, Azienda Ospedaliera S.G. Moscati, Avellino, Italy.lld:pubmed
pubmed-article:15015614pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:15015614pubmed:publicationTypeCase Reportslld:pubmed